nivolumab,ipilimumab
bms
['biomarker', 'marker ']
 that hot tumors are responsive? potentially may not even need combo. let s hope this secures biomarker testing for all cancers harboring msi, at diagnosis, not recurrence. rather than spend hours on the phone in p2p bickering with insurance companies to approve.
Tumor Immunology, TME, Systemic Immunity, Radiation Oncology, University of Colorado